Boston Scientific Corporation BSX

43.92 (0.76) (1.70%) as of 25 Sep
Market cap
$64.7B
P/E
17.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Boston Scientific Corporation (BSX) Free cash flow margin

Boston Scientific Corporation's free cash flow margin over the twelve months to 30 June 2026 was 17.3%, down 1.0 percentage points from fiscal 2025 (18.2%). Over the past ten years it has ranged from 0.08% (fiscal 2018) to 18.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Devices industry median of −7.24% and above the Healthcare sector median of 0.00%.

Free cash flow margin, annual

Annual

Period Free cash flow margin Change (points)
FY2025 18.2% 2.43
FY2024 15.8% 3.21
FY2023 12.6% 5.09
FY2022 7.49% (3.70)
FY2021 11.2% (0.35)
FY2020 11.5% (1.33)
FY2019 12.9% 12.79
FY2018 0.08% (12.15)
FY2017 12.2% 2.27
FY2016 9.96% 4.02

Against its own ten years

Low 0.08% High 18.2%
Ten-year median 11.5%
Current reading's percentile 100

Free cash flow margin against peers

Company Free cash flow margin
DXCM DexCom, Inc. compare 28.3%
EW Edwards Lifesciences Corporation compare 22.0%
SYK Stryker Corporation compare 18.2%
BSX Boston Scientific Corporation 17.3%
ABT Abbott Laboratories compare 16.8%
MDT Medtronic PLC compare 16.3%
STE STERIS plc compare 15.5%
PHG Koninklijke Philips N.V. compare 8.99%
GEHC GE HealthCare Technologies Inc. compare 7.42%
Medical Devices industry median −7.24%
Healthcare sector median 0.00%
Market median 0.00%

What Free cash flow margin is

Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.

(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue

The full definition of Free cash flow margin →

More on BSX